{"id":"apvac1-vaccine-plus-poly-iclc-and-gm-csf","safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"20%","effect":"Fatigue"},{"rate":"15%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4297559","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"APVAC1 vaccine is a personalized neoantigen vaccine that targets tumor-specific antigens, Poly-ICLC is an adjuvant that stimulates the innate immune response through Toll-like receptor 3, and GM-CSF is a cytokine that promotes the activation and maturation of antigen-presenting cells.","oneSentence":"APVAC1 vaccine targets tumor antigens, Poly-ICLC is a Toll-like receptor 3 agonist, and GM-CSF is a granulocyte-macrophage colony-stimulating factor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:53:58.749Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT02149225","phase":"PHASE1","title":"GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients","status":"COMPLETED","sponsor":"Immatics Biotechnologies GmbH","startDate":"2014-10","conditions":"Glioblastoma","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Actively Personalized Vaccine","Hiltonol","Leukine"],"phase":"phase_1","status":"active","brandName":"APVAC1 vaccine plus Poly-ICLC and GM-CSF","genericName":"APVAC1 vaccine plus Poly-ICLC and GM-CSF","companyName":"Immatics Biotechnologies GmbH","companyId":"immatics-biotechnologies-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APVAC1 vaccine targets tumor antigens, Poly-ICLC is a Toll-like receptor 3 agonist, and GM-CSF is a granulocyte-macrophage colony-stimulating factor. Used for Non-small cell lung cancer, Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}